# IMmotion151 (NCT02420821)

> A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02420821
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Renal Cell Carcinoma
- Interventions: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Bevacizumab; Sunitinib
- Enrollment: 915
- Primary outcome: Percentage of Participants With Disease Progression as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Death From Any Cause in Programmed Death-Ligand 1 (PD-L1)-Selected Population
- Primary outcome: Progression-Free Survival (PFS) as Determined by the Investigator According to RECIST v1.1 in PD-L1-Selected Population
- Primary outcome: Percentage of Participants Who Died of Any Cause in ITT Population
- Primary outcome: Overall Survival (OS) in ITT Population

## Commentary we found

- X threads: 19
- Podcasts: 10
- YouTube: 6
- X videos: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=immotion151-nct02420821

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02420821", "email": "<work email>"}; the inbox owner confirms by the emailed link.